Home
    • Plans Blog Contact
    PolyPid logo

    PolyPid

    PYPD
    Last price US$4.78
    Market cap US$87.0m
    12M price change 40.18%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    PharmaCyte Biotech IncPMCB Industry peer Abcam PLCABCM Industry peer Kiora Pharmaceuticals IncKPRX Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    PolyPid Overview

    Industry: Pharmaceuticals

    Sector: Healthcare

    PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (b Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for PolyPid into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 12, 2026

    Quarterly result summary

    Revenue was $3.7M (reported). Net loss was -$0M.

    Revenue $3.7M reported
    Net loss -$0M reported

    What changed

    • Revenue reported to $3.7M.

    Guidance / outlook

    We expect to continue to incur significant expenses and operating losses for the foreseeable future, and our losses may fluctuate significantly from year to year.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    Earnings release PRESS RELEASE ISSUED BY POLYPID LTD. ON AUGUST 12, 2026, TITLED "POLYPID PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS." Aug 12, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Aug 12, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Jul 29, 2026 Earnings release PRESS RELEASE ISSUED BY POLYPID LTD. ON JULY 29, 2026, TITLED "POLYPID ANNOUNCES FDA ACCEPTANCE OF NDA WITH PRIORITY REVIEW FOR D-PLEX100." Jul 29, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Jul 21, 2026 Earnings release PRESS RELEASE ISSUED BY POLYPID LTD. ON JULY 21, 2026, TITLED "POLYPID ANNOUNCES EXCLUSIVE PARTNERSHIP WITH AZURITY PHARMACEUTICALS FOR THE COMMERCIALIZATION OF D-PLEX100 IN THE U.S. AND CANADA." Jul 21, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Jun 01, 2026 Earnings release PRESS RELEASE ISSUED BY POLYPID LTD. ON JUNE 1, 2026, TITLED "POLYPID COMPLETES NEW DRUG APPLICATION SUBMISSION TO FDA FOR D-PLEX100" Jun 01, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER May 13, 2026 Earnings release PRESS RELEASE ISSUED BY POLYPID LTD. ON MAY 13, 2026, TITLED "POLYPID PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS." May 13, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Mar 31, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 1.00/5
    PolyPid earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Pharmaceuticals industry , PharmaCyte Biotech Inc , Abcam PLC , Kiora Pharmaceuticals Inc are companies with high ratings.

    Return on Equity

    Score 0.06/5
    PolyPid exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    PolyPid PYPD US$87.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    PolyPid olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    PolyPid PYPD US$87.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Pharmaceuticals industry , PharmaCyte Biotech Inc , Abcam PLC , Kiora Pharmaceuticals Inc are companies with high ratings.

    Leverage

    Score 3.32/5
    PolyPid attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    PolyPid PYPD US$87.0m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    PolyPid logo

    PolyPid

    US$4.78

    US$87.0m

    -1.44%

    40.18%